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Left ventricular (LV) hypertrophy (LVH), detected
either by electrocardiography (ECG) or echocardiogra-
phy (ECHO), has long been recognized as a powerful
predictor of serious cardiovascular (CV) sequelae.1,2 A
very large and highly consistent body of evidence
indicates that LVH is not only an adaptation to
increased hemodynamic load in hypertension, but is
also independently associated with an enhanced risk for
myocardial infarction, cardiac sudden death, congestive
heart failure, and stroke in the general population, as
well as in patients with systemic hypertension, coronary
heart disease, chronic kidney disease, and atrial fibril-
lation.1–5 Intriguingly, the cumulative incidence of
cardiovascular events increases progressively with
increasing LV mass (LVM), without evidence of any
threshold separating the postulated “compensatory”
from “pathological” LVH.3 In other words, patients
with LVM in the upper-normal range already have
increased risk for CV events.3
Moreover, various studies suggest that LVH reversal
is beneficial beyond blood pressure (BP) reduction and
treatment by demonstrating that CV events occur in a
higher proportion of individuals in whom LVH pro-
gresses rather than regresses.6
There are several determinants for the development of
LVH. Hemodynamic factors such as BP, large artery
structure and stiffness, and volume load are important.
In addition, nonhemodynamic mechanisms such as
trophic factors mediated by the sympathetic nervous
system, the renin-angiotensin-aldosterone system, and
other neurohormonal mediators play an important role
in the development of LVH.5,7
ECHO is more sensitive than ECG in diagnosing LVH
and may help in the more precise stratification of overall
risk and in the determination of therapy for hyperten-
sive patients.7,8
Furthermore, ECHO measurement of LV cavity size
and of myocardial relative wall thickness allows the
assessment of LV geometry.7,8 The traditional classifi-
cation of LV geometry in hypertensive heart disease
comprised the condition of normal LVM and geometry
and three abnormal LV geometric patterns: concentric
LV remodeling, eccentric LVH, and concentric
LVH.5,7,8 These LV geometric patterns have been
associated with different demographic and clinical
characteristics including age, sex, metabolic factors,
BP levels, LV systolic and diastolic function, hemody-
namic profile, extracardiac target organ damage, and
CV morbidity and mortality. In particular, it has been
reported that concentric LVH, connoting severe pres-
sure overload, is associated with worse outcome than
eccentric LVH or concentric remodeling.7,8 However,
whether abnormal LV geometric patterns carry prog-
nostic information beyond that provided by LV mass
remains uncertain. More recently, the investigators of
the Dallas Heart Study (DHS)9 refined this classification
of hypertensive LV geometric abnormalities by intro-
ducing the concept that LVH could exist in dilated or
nondilated forms, adding concentric dilated and nondi-
lated as well as eccentric dilated and nondilated
subtypes.9 The authors of the DHS suggested that
eccentric LVH with no dilatation appeared to provide a
lower risk for coronary artery disease and myocardial
function impairment than in the remaining three groups
of cardiac hypertrophy.9 However, this cross-sectional
study did not present results on outcome, and the
subsequent prospective investigations yielded conflicting
results regarding the prognostic role of these new
subtypes of LV geometric abnormalities.10,11
Nevertheless, the correct indication for ECHO in
hypertensive patients is still a matter of debate.12
Indeed, advocating ECHO for the assessment of LVH
in all hypertensive individuals would have enormous
cost implications, as a result of the high number of
patients. This imaging modality is more time-consuming
than ECG and requires considerable skill to perform.
Even though more accurate and sophisticated modal-
ities to diagnose LVH exist, such as ECHO, computer-
ized tomography, magnetic resonance, and, more
recently, three-dimensional ECHO, ECG remains the
first-choice technique to diagnose LVH in patients with
hypertension because it is widely available, easy to
perform, specific, inexpensive, reproducible, and of
established prognostic value.13 ECG can also be used
to detect patterns of ventricular overload or “strain”
(known to indicate more severe risk), ischemia, con-
duction defects, and arrhythmias.8,13 Current guidelines
for the management of hypertension8,14 strongly rec-
ommend ECG as the only examination to be performed
in all hypertensive patients for detection of LVH.
Even if ECG assessment of LVH has been incorpo-
rated among standard tests in hypertension guidelines, a
recent Italian survey showed that such a recommenda-
tion is largely ignored in current clinical practice.
Indeed, in this survey, <40% of the study sample had
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undergone ECG during the 12-month period preceding
ECHO examination.15
Moreover, in recent years, many studies have
addressed the value of new ECG markers (fragmented
QRS, ventricular activation time, P-wave analysis, P-
wave dispersion, peak-to-end time interval of T wave) in
detecting subclinical cardiac damage and predicting CV
outcome, with promising results.16,17
Despite the limited sensitivity of ECG for LVH
compared with ECHO, a recent analysis in a population
of 40,444 hypertensive patients from 26 studies pub-
lished in the past decade documented that ECG LVH is
a frequent marker of hypertensive heart disease, being
detected in 18% of the pooled population.18
In the current issue of the Journal, Cuspidi and
coworkers19 evaluated the combined prognostic impact
of ECG and ECHO indices of LVH by analyzing the
data obtained in the Pressioni Arteriose Monitorate E
Loro Associazioni (PAMELA) study, a population study
performed in a north region of Italy. They found that
the association of ECG LVH with ECHO LVH signif-
icantly increased the risk of CV mortality independently
of other risk factors known to predict mortality.19 This
was also true when ECG LVH was combined with some
subtypes of ECHO LVH, such as concentric LVH and
eccentric nondilated LVH. LVH as assessed by ECHO
only showed borderline statistical significance.19
These findings seem to corroborate the concept that
ECG and ECHO are complementary and not competing
methods, eachproviding its ownrelevant information.13,20
Computer simulation studies20 have shown that the
increase in voltage and duration of the QRS complex of
ECG do not have a straightforward relationship with
LV mass. In other words, the so-called ECG LVH is not
totally a reflection of increase in LV mass, but could be
secondary to increased myocardial tension, disturbances
of intraventricular electrical conduction, or neurohu-
moral and/or biochemical changes in the myocardium.20
Moreover, some ECG criteria (such as LV strain, not
assessed in the paper by Cuspidi and coworkers19) may
reflect the subendocardial ischemia that is often associ-
ated with LVH.
However, there may be important diagnostic infor-
mation hidden in this apparent discrepancy that needs
to be fully explored.
The idea that ECG LVH could be a separate entity
from imaging-based LVH is further supported by a
genome-wide linkage analysis of ECG LVH and ECHO
LVH in families with hypertension that showed stronger
genetic signals for ECG LVH than ECHO LVH, and
that the genetic determinants of each of these appear to
be distinct.21
The findings by Cuspidi and coworkers are in
agreement with previous data in the literature.22–26
Sundstrom and coworkers22 showed that the prognostic
value of ECG LVH (diagnosed employing the Cornell
product) is, to some extent, independent of ECHO-LV
mass index in a population-based sample of 475
Swedish elderly men.
In the second Strong Heart Study, 2193 American
Indians underwent both ECG and ECHO and were
followed up over an average of 3 years. The presence of
both ECHO LVH and ECG ST depression was associ-
ated with a 6.3-fold increased risk of CV death in this
group of patients.23 Similar results were obtained in
another study in which ECG LVH was associated with
incident ischemic stroke after adjustment for ECHO
LVH.24
Moreover, an analysis of hypertensive patients from
the Losartan Intervention For Endpoint Reduction in
Hypertension (LIFE) study25 showed that people with
both forms of LVH tended to have greater evidence of
cardiac disease and were more likely to be hospitalized
for heart failure.
More recently, in a large prospective population-
based investigation (the Oregon Sudden Unexpected
Death Study), ECG LVH was significantly associated
with sudden cardiac death. This association was only
mildly attenuated when ECHO LVH was taken into
account in multivariate analysis, and ECHO LVH was
also independently associated with sudden cardiac
death.26
The report by Cuspidi and coworkers provides a new
piece of evidence in this scenario by adding the new
finding that the additional prognostic value of ECG
LVH is maintained even when ECHO LVH was
classified in subtypes of geometric pattern, as defined
by the updated classification proposed by DHS investi-
gators.9
CONCLUSIONS
The study by Cuspidi and coworkers confirms that the
traditional interpretation of standard ECG maintains an
important role for CV risk stratification in hypertension
and supports the notion that, in the assessment of
hypertensive heart disease, ECG needs to be regarded as
a much more important tool than previously thought,
because its prognostic value seems to surpass its limited
ability to detect LVH.
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